

AMENDMENTS

TO THE CLAIMS:

1-13. (Cancelled)

14. (Currently Amended) A method of eliciting or boosting a cellular immune response to an antigen in a subject, said method comprising:
administering to said subject an effective amount of *Listeria* cells that express said antigen, wherein said cells are transformed with an integration vector capable of integrase mediated site-specific *Listeria* genome integration, wherein said integration vector comprises a *listeriophage* attachment site **and a nucleic acid sequence encoding a *listeriophage* integrase.**

15. (Original) The method according to Claim 14, wherein said *Listeria* cells are attenuated.

16-24. (Cancelled)

25. (Previously presented) The method according to Claim 14, wherein said integration vector is a plasmid.

26. (Previously Presented) The method according to Claim 25, wherein said plasmid comprises a bacteriophage integrase gene.

27. (Cancelled)

28. (Previously presented) The method according to Claim 26, wherein said attachment site provides for integration at an integration site selected from the group consisting of: the *comK* integration site and the tRNA^{A9} integration site.

29. (Previously presented) The method according to Claim 14, wherein said integration vector further includes a multiple cloning site.

30. (Previously presented) The method according to Claim 29, wherein said integration vector further includes a coding sequence.

31. (Previously presented) The method according to Claim 30, wherein said coding sequence encodes a polypeptide.

32. (Previously presented) The method according to Claim 31, wherein said polypeptide is said antigen.

33. (Previously Presented) The method according to Claim 14, wherein said integration vector is pPL1.

34. (Previously presented) The method according to Claim 14, wherein said integration vector is pPL2.

35. (Cancelled)